Lawmakers push FDA to close loophole allowing import of counterfeit Eli Lilly obesity drug

A bipartisan group of U.S. lawmakers is urging the Food and Drug Administration to address a regulatory gap that permits the importation of unapproved versions of retatrutide, an experimental obesity treatment being developed by Eli Lilly.

The lawmakers argue that the loophole enables foreign manufacturers to market knock‑off copies of the peptide, potentially undermining safety standards and the integrity of clinical data.

They have written to the FDA requesting clarification of the existing policy and the implementation of stricter controls to prevent such imports, citing concerns for patient safety and fair competition.

The FDA has not yet responded publicly, and the issue adds to ongoing scrutiny of how peptide‑based drugs are regulated as they move toward market approval.